


**SECTION 1: PRODUCT IDENTIFICATION**

<b>PRODUCT NAME</b>	<b>LANSOPRAZOLE, USP</b>
<b>PRODUCT CODE</b>	<b>2289</b>
<b>SUPPLIER</b>	<b>MEDISCA Inc.</b> Tel.: 1.800.932.1039   Fax.: 1.855.850.5855 626 Tom Miller Road, Plattsburgh, NY, 12901 <b>MEDISCA Pharmaceutique Inc.</b> Tel.: 1.800.665.6334   Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8 <b>MEDISCA Australia PTY LTD</b> Tel.: 1.300.786.392   Fax.: 61.2.9700.9047 Unit 7, Heritage Business Park 5-9 Ricketty Street, Mascot, NSW 2020
<b>EMERGENCY PHONE</b>	CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300 NSW Poisons Information Centre: 131 126 National Chemical Emergency Centre 44(0)1235239670
<b>RECOMMENDED USES</b>	Pharmaceutical Manufacturing
<b>RESTRICTIONS ON USE</b>	Not applicable

**SECTION 2: HAZARDS IDENTIFICATION**

<b>GHS CLASSIFICATION</b>	Sensitization - Skin (Category 1) Carcinogenicity (Category 2)	
<b>PICTOGRAM</b>		
<b>SIGNAL WORD</b>	Warning	
<b>HAZARD STATEMENT(S)</b>	May cause an allergic skin reaction. Suspected of causing cancer.	
<b>ADVERSE PHYSIOCHEMICAL, HUMAN HEALTH AND ENVIRONMENTAL EFFECTS</b>	Repeated exposure may cause skin dryness or cracking.	
<b>PRECAUTIONARY STATEMENT(S)</b>	<b>Prevention</b>	Avoid breathing dust, fume, gas, mist, vapors, and spray. Contaminated work clothing should not be allowed out of the workplace. Obtain, read and follow all special instructions before use. Do not handle until all safety precautions have been read and understood. Wear protective gloves, protective clothing, eye and face protection and hearing protection.
	<b>Response</b>	IF ON SKIN: Wash with plenty of water. If skin irritation or rash occurs: Get medical help advice/attention. Take off contaminated clothing and wash it before reuse. IF EXPOSED OR CONCERNED: Get medical advice.

HMIS CLASSIFICATION	<b>Storage</b>	Store locked up.		
	<b>Disposal</b>	Dispose of contents and/or container in accordance with local regulations.		
	<b>Health Hazard</b>	2	<b>Flammability</b>	0
	<b>Reactivity</b>	0	<b>Personal Protection</b>	F

### SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

<b>CHEMICAL NAME</b>	1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-
<b>BOTANICAL NAME</b>	Not applicable
<b>SYNONYM</b>	Not applicable
<b>CHEMICAL FORMULA</b>	C <sub>16</sub> H <sub>14</sub> F <sub>3</sub> N <sub>3</sub> O <sub>2</sub> S
<b>CHEMICAL FAMILY</b>	Substituted benzimidazole
<b>CAS NUMBER</b>	103577-45-3
<b>ALTERNATE CAS NUMBER</b>	Not applicable
<b>MOLECULAR WEIGHT</b>	369.36

CHEMICAL NAME	CAS NUMBER	EC NUMBER	% BY WEIGHT
LANSOPRAZOLE	103577-45-3	627-144-2	100

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as health hazards and hence require reporting in this section.

**NOTES** Lansoprazole is a proton pump inhibitor with actions and uses similar to those of omeprazole.

### SECTION 4: FIRST-AID MEASURES

<b>IN CASE OF EYE CONTACT</b>	Flush with copious amounts of water for 15 minutes, separating eyelids with fingers. If irritation persists seek medical aid.
<b>IN CASE OF SKIN CONTACT</b>	Wash with soap & water for 15 minutes. If irritation persists seek medical aid.
<b>IF SWALLOWED</b>	Call a physician. Wash out mouth with water. Do not induce vomiting without medical advice.
<b>IF INHALED</b>	Remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Call a physician
<b>MEDICAL ATTENTION AND SPECIAL TREATMENT</b>	Get emergency medical help.
<b>SYMPTOMS CAUSED BY EXPOSURE</b>	Not expected to present a significant hazard under anticipated conditions of normal use.

### SECTION 5: FIREFIGHTING MEASURES

<b>SPECIFIC HAZARDS ARISING FROM THE CHEMICAL</b>	Dust can combine with air to form an explosive mixture.
<b>FLAMMABLE PROPERTIES</b>	May be combustible at high temperature.
<b>HAZARDOUS COMBUSTION PRODUCTS</b>	Under fire conditions, hazardous fumes will be present.

**SUITABLE & UNSUITABLE  
EXTINGUISHING MEDIA**

**Small fire:** dry chemical, CO<sub>2</sub> or water spray. **Large fire:** dry chemical, CO<sub>2</sub>, alcohol resistant foam or water spray. Do not get water inside containers.

**PROTECTIVE EQUIPMENT AND  
PRECAUTIONS FOR  
FIREFIGHTERS**

Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.

**SECTION 6: ACCIDENTAL RELEASE MEASURES**
**PERSONAL PRECAUTIONS**

Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.

**METHODS & MATERIAL FOR  
CONTAINMENT**

On land, sweep or shovel into suitable containers. Minimize generation of dust.

**CLEANUP PROCEDURE**

Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Wear respirator, chemical safety goggles, rubber boots and heavy rubber gloves. Stop leak if you can do it without risk. Prevent entry into waterways, sewers, basements or confined areas. Shut off all sources of ignition. Evacuate the area. If necessary, employ water fog to disperse the vapors. Absorb the matter with compatible vermiculite or other absorbing material. Place in a suitable container and retain for disposal. Ventilate and clean the affected area. Do not flush into sewerage system or to drains.

**REFERENCE TO OTHER  
SECTIONS**

See Section 7 for information on safe handling. See Section 8 for information on personal protection equipment. See Section 13 for disposal information.

**SECTION 7: HANDLING AND STORAGE**
**PRECAUTIONS FOR SAFE  
HANDLING**

Do not inhale. Avoid contact with eyes, skin and clothing. Avoid prolonged or repeated exposure. Wash thoroughly after handling. Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabeled containers. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Use appropriate containment to avoid environmental contamination.

**CONDITIONS FOR SAFE  
STORAGE**

Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabeled containers. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Use appropriate containment to avoid environmental contamination.

**STORAGE CONDITIONS**

Store in original container, tightly sealed, protected from direct sunlight and moisture.

Short term excursions, temperature excursions as experienced during shipping and warehousing, up to 40°C are acceptable.

**SECTION 8: EXPOSURE CONTROLS/ PERSONAL PROTECTION**

Chemical Name: LANSOPRAZOLE CAS #: 103577-45-3

	Country	Limit value-8 hours		Limit value-Short Term		IDLH	REL	Advisory	Notes
		ppm	mg/m <sup>3</sup>	ppm	mg/m <sup>3</sup>				
OSHA	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
ACGIH	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
NIOSH	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
WEEL	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A

<b>HSIS</b>	Australia	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
<b>HSE</b>	UK	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
<b>GESTIS</b>	Add Country	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A

N/L = Not listed ; N/A = Not Available

PELs are 8-hour TWAs = Limit value - Eight hours

Ceiling or Short-Term TWA = STEL = Limit value - Short term

**EXPOSURE GUIDELINES**

Consult local authorities for provincial or state exposure limits. Particulates not otherwise regulated, respirable fraction: 5 mg/m<sup>3</sup>

**PERSONAL PROTECTIVE EQUIPMENT**

**Eyes:** Wear appropriate protective eyeglasses or chemical safety goggles as described by WHMIS or OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. **Skin:** Wear appropriate gloves to prevent skin exposure. **Clothing:** Wear appropriate protective clothing to minimize contact with skin. **Respirators:** Follow WHMIS or OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. **Thermal Hazards:** For products representing a thermal hazard, appropriate Personal Protective Equipment should be used.

**SPECIFIC ENGINEERING CONTROLS**

Adequate mechanical ventilation. Fumehood, eye wash station, and safety shower.

**BIOLOGICAL MONITORING**

Not available

**CONTROL BANDING**

Not available

**SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**
**PHYSICAL STATE**

Solid

**DESCRIPTION**

White to brownish-white hygroscopic powder.

**SOLUBILITY**

Freely soluble in dimethylformamide; practically insoluble in water.

**ODOR**

Odorless

**FLAMMABILITY**

May be combustible at high temperature

**AUTO-IGNITION TEMPERATURE**

Not available

**BOILING POINT**

555.8 °C,  
1032.44 °F (760 mmHg)

**DECOMPOSITION TEMPERATURE**

(178 - 182) °C,  
(352.4-359.6) °F

**EVAPORATION RATE**

Not available

**EXPLOSIVE LIMIT**

Not available

**FLASH POINT**

289.9 °C, 553.82 °F

**log P (OCTANOL-WATER)**

2.58 (20°C)

**LOWER FLAMMABLE/EXPLOSIVE LIMIT(S)**

Not available

**MELTING/FREEZING POINT**

(178 - 182) °C,  
(352.4-359.6) °F  
(decomposes)

**PARTICLE CHARACTERISTICS**

Not available

**OXIDIZING PROPERTY**

Not available

**pH**

Not available

**RELATIVE DENSITY (WATER = 1)**

1.5 g/cm<sup>3</sup>

**SPECIFIC GRAVITY**

Not available

**UPPER FLAMMABLE/EXPLOSIVE LIMIT(S)**

Not available

**VAPOR DENSITY  
(AIR = 1)**

Not available

**VAPOR PRESSURE**

Not available

**VISCOSITY**

Not available

The physical data presented above are typical values and should not be construed as a specification.



## SECTION 10: STABILITY AND REACTIVITY

**REACTIVITY**

Not established.

**CHEMICAL STABILITY**

Stable under recommended storage conditions.

**INCOMPATIBLE MATERIALS**

Strong oxidants, strong bases, strong acids.

**HAZARDOUS DECOMPOSITION PRODUCTS**

Toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides and other gases may occur.

**HAZARDOUS POLYMERIZATION**

Will not occur.

**POSSIBILITY OF HAZARDOUS REACTION**

Not established.

**CONDITIONS TO AVOID**

 Moisture, sunlight and extreme temperatures.  
 Hygroscopic - Avoid exposure to moisture.

## SECTION 11: TOXICOLOGICAL INFORMATION

**ACUTE TOXICITY**

 Oral: Rat: LD50: (mg/kg): > 5000  
 Dermal: Rabbit: LD50: (mg/kg): Not available  
 Inhalation: Rat: LC50: (mg/L/4hr): Not available

**SKIN CORROSION/IRRITATION**

Due to lack of data the classification is not possible.

**SERIOUS EYE DAMAGE/EYE IRRITATION**

Due to lack of data the classification is not possible.

**RESPIRATORY SENSITIZATION**

Due to lack of data the classification is not possible.

**SKIN SENSITIZATION**

 May cause an allergic skin reaction.  
 Guinea pig: Skin sensitization; Result: Positive.

**GERM CELL MUTAGENICITY**

 Due to lack of data the classification is not possible.  
 Ames test; Result: Positive.  
 Chromosome aberration; Result: Negative.  
 Chromosome aberration; Result: Positive.  
 Micronucleus test; Result: Negative.  
 Unscheduled DNA synthesis; Result: Negative.

**CARCINOGENICITY**

<b>OSHA</b>	LANSOPRAZOLE is not listed.
<b>NTP</b>	LANSOPRAZOLE is not listed.
<b>IARC</b>	LANSOPRAZOLE is not evaluated.
<b>California Proposition</b>	This product does not contain any chemicals known to the State of California to cause cancer, birth defects, or any other reproductive harm.

**ADDITIONAL CARCINOGENICITY  
INFORMATION**

Suspected of causing cancer.

Proton pump inhibitors increase serum gastrin, stimulating proliferation of gastric enterochromaffin-like (ECL) cells. Over time, this may result in ECL cell hyperplasia in rats and mice and gastric carcinoids in rats. Therapeutic use of proton pump inhibitors has not been conclusively associated with gastric cancer in humans.

Rat: < 150 mg/kg/day Carcinogenicity (2-year test); Result: Produced dose-related gastric enterochromaffin-like (ECL) cell hyperplasia and ECL cell carcinoids in both male and female rats.

Mouse: < 600 mg/kg/day Carcinogenicity (2-year test); Result: Increase in the incidence of liver tumors (hepatocellular adenomas and carcinomas), a dose-related increase in the incidence of gastric ECL cell hyperplasia, and adenomas of the rete testis in males.

Rat: 50 mg/kg/day Carcinogenicity (1-year test); Result: Testicular interstitial cell adenoma occurred in 1 of 30 rats.

**REPRODUCTIVE TOXICITY**

Based on available data, the classification criteria are not met.

Epidemiological studies have not shown an association between the use of proton pump inhibitors during pregnancy and an increased risk of birth defects.

Rat: < 150 mg/kg/day Reproductivity; Result: No effect on fertility or reproductive performance in male and female rats. No harm to fetus during pregnancy in female rats.

Rabbit: < 30 mg/kg/day Reproductivity; Result: No harm to fetus during pregnancy.

Rat: 3600 mg/kg Reproductivity ; Result: Fetotoxicity.

Rabbit: 390 mg/kg Reproductivity; Result: Fetal death

**SPECIFIC TARGET ORGAN  
TOXICITY - SINGLE EXPOSURE**

Due to lack of data the classification is not possible.

**SPECIFIC TARGET ORGAN  
TOXICITY - REPEATED  
EXPOSURE**

Due to lack of data the classification is not possible.

**ASPIRATION HAZARDS**

Based on available data, the classification criteria are not met.

**SIGNS AND SYMPTOMS OF  
EXPOSURE**

ROUTES OF EXPOSURE:  
Oral, Dermal, Inhalation, Eye contact

EARLY ONSET SYMPTOMS RELATED TO EXPOSURE:  
Not available

DELAYED HEALTH EFFECT FROM EXPOSURE:  
Not available

Medical conditions aggravated by exposure:  
Liver disease

Symptoms related to the physical, chemical, and toxicological characteristics:  
Proton pump inhibitors: Headache. Nausea. Vomiting. Diarrhea. Abdominal/stomach pain. Cramps. Constipation. Gas. Dizziness. Drowsiness. Cough. Chills. Fever. Sore throat. Confusion. Anxiety. Blurred vision. Loss of appetite. Chest pain. Joint pain. Tiredness. Weakness.

Cross sensitivity:  
Persons sensitive to one proton pump inhibitor may be sensitive to this material as well.

Cases of anaphylactic reactions after treatment with omeprazole, lansoprazole, and pantoprazole, have been reported in the literature and to WHO.

**POTENTIAL HEALTH EFFECTS**

<b>Inhalation</b>	May be harmful if inhaled. May cause respiratory tract irritation.
<b>Ingestion</b>	May be harmful if swallowed.
<b>Skin</b>	May be harmful if absorbed through skin. May cause skin irritation. May cause an allergic skin reaction.
<b>Eyes</b>	Causes serious eye irritation.

**SECTION 12: ECOLOGICAL INFORMATION**

<b>ECOTOXICITY</b>	EC50: 48 Hr: Crustacea: (mg/L): Not available LC50: 96 Hr: Fish: (mg/L): Not available EC50: 72 or 96 Hr: Algae (or other aqua plants): (mg/L): Not available
<b>PERSISTENCE AND DEGRADABILITY</b>	Biodegradation in natural media. Biodegradation: 76%.
<b>BIOACCUMULATIVE POTENTIAL</b>	Log Pow: 2.58 (20°C). Moderate bioaccumulative potential.
<b>MOBILITY IN SOIL</b>	Water solubility: 0.97 mg/L.
<b>OTHER ADVERSE EFFECTS</b>	Not available This product is not intended to be released into the environment.

**SECTION 13: DISPOSAL CONSIDERATIONS**

<b>DISPOSAL METHODS</b>	Dispose of in accordance with federal / local laws and regulations. Avoid release into the environment.
-------------------------	---

**SECTION 14: TRANSPORT INFORMATION**

<b>UN PROPER SHIPPING NAME</b>	Not dangerous good
<b>UN NUMBER</b>	Not applicable
<b>CLASS</b>	Not applicable
<b>PACKING GROUP</b>	Not applicable

<b>AUSTRALIA HAZCHEM</b>	Not applicable
------------------------------	----------------

<b>EU TRANSPORT IN BULK ACCORDING TO ANNEX II OF MARPOL 73/78 AND THE IBC CODE</b>	Not listed
--	------------

<b>ENVIRONMENTAL HAZARDS</b>	Not available
<b>SPECIAL SHIPPING INFORMATION</b>	Not applicable

**SECTION 15: REGULATORY INFORMATION**
**UNITED STATES REGULATIONS**

Chemical Name & CAS	CERCLA 40 CFR Part 302.4	SARA (Title III) 40 CFR	EPA 40 CFR Part 355		Pennsylvania	Right-to-know		California Prop 65
			Appendix A	Appendix B		New Jersey	Massachusetts	
LANSOPRAZOLE 103577-45-3	N/L	N/L	N/L	N/L	N/L	N/L	N/L	N/L

N/L = Not Listed; X = Listed

**AUSTRALIAN REGULATIONS**

Chemical Name & CAS	Poisons and Therapeutic Goods	Therapeutic Goods Act	Code of Practices - Illicit Drug	Poisons Standard	Work Health and Safety Regulations	Inventory of Industrial Chemicals
LANSOPRAZOLE 103577-45-3	N/L	Listed as Schedule 4	N/L	Listed	N/L	N/L

N/L = Not Listed

**EU REGULATIONS**

Chemical Name & CAS	REACH ANNEX XVII	REACH ANNEX XIV	EC 1005/2009	EC 850/2004	EC 1107/2009	PIC - Prior Informed Consent Regulation	EC 2012/18
LANSOPRAZOLE 103577-45-3	N/L	N/L	N/L	N/L	N/L	N/L	N/L

N/L = Not Listed; X = Listed

Any EU regulation not listed above is not applicable to this product.

SUBJECT TO INTERNATIONAL AGREEMENT Not applicable

**SECTION 16: OTHER INFORMATION**
**REFERENCES**

Available upon request

**ABBREVIATIONS AND ACRONYMS**

**ACGIH** - American Conference of Governmental Industrial Hygienists; **AIHA WEEL** – American Industrial Hygiene Association Workplace Environment Exposure Levels; **CAESAR** – Computer Assisted Evaluation of industrial chemical Substances According to Regulations; **CAS** – Chemical Abstract Service; **CERCLA** – Comprehensive Environmental Response, Compensation, and Liability Act; **EC50** – Effective Concentration, 50%; **EPA** – Environmental Protection Agency; **GHS** – Global Harmonized System; **HMIS** – Hazardous Materials Information System; **HSE** – Health and Safety Executive; **HSIS** – Hazardous Substances Information System; **IARC** – International Agency for Research on Cancer; **IDLH** - Immediately Dangerous to Life or Health; **IRFMN** – Ready Biodegradability Model; **ISS** – Istituto Superiore Sanità; **LC50** – Lethal Concentration, 50%; **LD50** – Lethal Dose, 50%; **MSHA** - Mine Safety and Health Administration; **NIOSH** – National Institute for Occupational Safety and Health; **NTP** – National Toxicology Program; **OSHA PEL** – Occupational Safety & Health Administration Permissible Exposure Limits; **QSAR** – Quantitative Structure-activity relationship; **REL** - Recommended Exposure Limit; **SARA** – Superfund Amendments and Reauthorization Act; **STEL** – Short Term Exposure Limit; **TLV** – Threshold Limit Value; **TWA** – Time Weighted Average; **WHMIS** – Workplace Hazardous Materials Information System

**LAST REVISION**

03/2023

**SUPERSEDES**

05/2021

For a list of changes to the SDS since the last version, please communicate with MEDISCA at [www.medisca.com](http://www.medisca.com)

**DISCLAIMER**

This document was created in accordance with OSHA, Safe Work Australia and WHMIS regulations. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. MEDISCA® shall not be held liable for any damage resulting from handling or from contact with the above product. Recipients of the product must take responsibility for observing existing laws and regulations.

**SUPPLEMENTARY INFORMATION**

For all country specific requirements not outlined on this Safety Data Sheet, please request Supplementary Page to this Safety Data Sheet.